Author

M. Porru

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Biroccio· 1 shared A. Harris· 1 shared A. Londono· 1 shared A. Miar· 1 shared B. Wright· 1 shared C. A. Amoreo· 1 shared C. Cristofoletti· 1 shared C. Leonetti· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Biroccio

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling

G. Cristinziano, M. Porru, D. Lamberti, S. Buglioni, F. Rollo, C. A. Amoreo, I. Manni, D. Giannarelli, C. Cristofoletti, G. Russo, M. J. Borad, G. L. Grazi, M. G. Diodoro, S. Giordano, M. Forcato, , O. Segatto

This paper develops FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma and shows that Erk signaling is essential for tumor growth, with double blockade of FF-Ras-Erk pathways improving therapeutic efficacy.

bioRxiv · May 20, 2020 · PreprintCancer Biology

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

T. Reislander, E. Puig Lombardi, F. J. Groelly, A. Miar, M. Porru, B. Wright, H. Lockstone, A. Biroccio, A. Harris, A. Londono, M. Tarsounas

This study shows that BRCA2 loss in cancer cells triggers innate immune responses, which are enhanced by PARP inhibitors, suggesting a mechanism for their therapeutic effect.

bioRxiv · Dec 10, 2018Cancer Biology